Antidepressant-like effects of the novel kappa opioid antagonist MCL-144B in the forced-swim test

Pharmacology

Volumn 81, Issue 3, 2008, Pages 229-235

  Reindl, J D ^a   Rowan, K ^a   Carey, A N ^a   Peng, X ^b   Neumeyer, J L ^b   McLaughlin, J P ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b MCLEAN HOSPITAL   (United States)

Author keywords

Depression; Kappa receptors; Mixed agonist antagonist; Opioids; Stress

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; BIS(N CYCLOBUTYLMETHYLMORPHINAN 3 YL)SEBACOYLATE; KAPPA OPIATE RECEPTOR ANTAGONIST; MCL 144B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG STRUCTURE; FORCED SWIMMING TEST; IMMOBILIZATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRESS;

ALKANES; ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; IMMOBILIZATION; MALE; MICE; MICE, INBRED C57BL; MORPHINANS; RECEPTORS, OPIOID, KAPPA; STRESS, PSYCHOLOGICAL; SWIMMING; TIME FACTORS;

EID: 41349119354     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112867     Document Type: Article

References (26)

1. Kessler RC, Chiu WT, Demler O, Walters EE: Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Arch Gen Psychiatry 2005;62:617-627.
2. Baker CB: Quantitative analysis of sponsorship bias in economic studies of antidepressants. Br J Psychiatry 2003;183:498-506.
3. McLaughlin JP, Marton-Popovici M, Chavkin C: KOR antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci 2003;23:5674-5683.
4. Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, Stevens WC Jr, Jones RM, Portoghese PS, Carlezon WA Jr: Antidepressant-like effects of KOR antagonists in the forced swim test in rats. J Pharmacol Exp Ther 2003;305:323-330.
5. Beardsley PM, Howard JL, Shelton KL, Carroll FI: Differential effects of the novel KOR antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology 2005;183:118-126.
6. McLaughlin JP, Land BB, Li S, Pintar JE, Chavkin C: Prior activation of KORs by U50,488 mimics repeated forced swim stress to potentiate cocaine place preference conditioning. Neuropsychopharmacology 2006;31:787-794.
7. Porsolt RD, Bertin A, Jalfre M: Behavioural despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977;229:327-336.
8. Carlezon WA Jr, Béguin C, DiNieri JA, Baumann MH, Richards MR, Todtenkopf MS, Rothman RB, Ma Z, Lee D Y-W, Cohen BM: Depressive-like effects of the KOR agonist Salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther 2006;316:440-447.
9. Neumeyer JL, Zhang A, Ziong W, Gu X, Hilbert JE, Knapp B, Negus SS, Mello NM, Bidlack JM: Design and synthesis of novel dimeric morphinan ligands for kappa and mu opioid receptors. J Med Chem 2003;46:5162-5170.
10. Lucki I, Ashutosh D, Mayorga AJ: Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology 2001;155:315-322.
11. Vaught JL, Takemori AE: Differential effects of leucine and methionine enkephalin on morphine-induced analgesia, acute tolerance and dependence. J Pharmacol Exp Ther 1979;208:86-90.
12. McLaughlin JP, Hill KP, Jiang Q, Sebastian A, Archer S, Bidlack JM: Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity. J Pharmacol Exp Ther 1999;289:304-311.
13. McLaughlin JP, Nowak D, Sebastian A, Shultz AG, Archer S, Bidlack JM: Metopon and two unique derivatives: affinity and selectivity for the multiple opioid receptors. Eur J Pharmacol 1995;294:201-206.
14. Cryan JF, Valentino RJ, Lucki I: Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 2005;29:547-569.
15. Husbands SM, Neilan CL, Broadbear J, Grundt P, Breeden S, Aceto MD, Woods JH, Lewis JW, Traynor JR: BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism. Eur J Pharmacol 2005;509:117-125.
16. Akil H, Mayer DJ, Liebeskind JC: Antagonism of stimulation-produced analgesia by naloxone, a narcotic antagonist. Science 1976;191:961-962.
17. Horan P, Taylor J, Yamamura HI, Porreca F: Extremely long-lasting antagonistic actions of nor-Binaltorphimine (nor-BNI) in the mouse tail-flick test. J Pharmacol Exp Ther 1992;260:1237-1243.
18. Carroll I, Thomas JB, Dykstra LA, Granger AL, Allen RM, Howard JL, Pollard GT, Aceto MD, Harris LS: Pharmacological properties of JDTic: a novel κ-opioid receptor antagonist. Eur J Pharmacol 2004;501:111-119.
19. Piazza PV, Deminiere JM, Maol ML, Simon H: Stress- and pharmacologically induced behavioral sensitization increases vulnerability to acquisition of amphetamine self-administration. Brain Res 1990;514:22-26.
20. Przewlocki R, Lason W, Holt V, Silberring J, Herz A: The influence of chronic stress on multiple opioid peptide systems in the rat; pronounced effects upon dynorphin in spinal cord. Brain Res 1987;413:213-219.
21. Shirayama Y, Ishida H, Iwata M, Hazama GI, Kawahara R, Duman RS: Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. J Neurochem 2004;90:1258-1268.
22. Takahashi M, Senda T, Tokuyama S, Kaneto H: Further evidence for the implication of a kappa-opioid receptor mechanism in the production of psychological stress-induced analgesia. Jpn J Pharmacol 1990;53:487-494.
23. Reyes BA, Johnson AD, Glaser JD, Commons KG, Van Bockstaele EJ: Dynorphin-containing axons directly innervate noradrenergic neurons in the rat nucleus locus coeruleus. Neuroscience 2006;145:1077-1086.
24. Fichna J, Janecka A, Piestrzeniewicz M, Costentin J, do Rego JC: Antidepressant-like effect of endomorphin-1 and endomorphin-2 in mice. Neuropsychopharmacology 2007;32:813-821.
25. Eschalier A, Rigal F, Devoize JL, Trolese JF, Grillon C: Morphine pretreatment reduces clomipramine effect in mouse forced-swimming test. Eur J Pharmacol 1983;91:505-507.
26. Broom DC, Jutkiewicz EM, Folk JE, Traynor JR, Rice KC, Woods JH: Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats. Neuropsychopharmacology 2002;26:744-755.